Back to mobile site

Seattle Genetics (SGEN) Submits BLA for Brentuximab Vedotin to U.S. FDA

February 28, 2011 6:52 AM EST Send to a Friend
Seattle Genetics, Inc. (Nasdaq: SGEN) has submitted a Biologics License Application (BLA) to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login